Primmune Therapeutics Presents Data Evaluating PRTX007 as an Antiviral at the 35th International Conference on Antiviral Research (ICAR) - Yahoo Finance

SAN DIEGO, March 21, 2022--Primmune Therapeutics presents data on its lead candidate PRTX007 at ICAR 2022.

PRTX007 exhibits activation of the innate immune system in both cellular and murine animal models against respiratory syncytial virus (RSV) Findings demonstrate broad-spectrum antiviral activity a… [+4883 chars]

full article...